Melanocortins

Melanocortins are peptides derived from the proopiomelanocortin (POMC) precursor — most prominently α-MSH (alpha-melanocyte-stimulating hormone), the 13-residue pigmentation hormone — together with synthetic analogs that have been developed for pigmentation, hypothalamic obesity, sexual desire, and cosmetic applications. The family signals through five melanocortin receptors (MC1R-MC5R) with characteristic tissue distributions: MC1R for skin pigmentation, MC2R for adrenocortical function (the ACTH receptor), MC3R and MC4R for hypothalamic energy homeostasis, and MC5R for sebaceous and exocrine functions. The clinical translation of the family covers three established indications and several research-tier ones: afamelanotide (Scenesse, an MC1R-selective α-MSH analog) is FDA- and EMA-approved for erythropoietic protoporphyria; setmelanotide (Imcivree, an MC4R agonist) is FDA-approved for monogenic obesity from POMC, PCSK1, LEPR, and BBS deficiency; bremelanotide (Vyleesi / PT-141, an MC3R/MC4R agonist) is FDA-approved for hypoactive sexual desire disorder in premenopausal women; and the research-channel agents melanotan-I and melanotan-II are widely sold for cosmetic tanning despite no clinical approval. The cosmetic peptide nonapeptide-1 (Pal-MeMSH-9) is an MC1R-targeted depigmenting agent in topical brightening formulations, and the antimicrobial peptide KPV is the C-terminal tripeptide fragment of α-MSH with anti-inflammatory activity in the gut.

This page is the family-level pillar covering the melanocortin class as a whole. For individual peptide pages with full evidence ratings, dosing, and references, follow the links to each member below.

Shared mechanism

All members of the melanocortin family signal through the five melanocortin receptors (MC1R-MC5R), which are class A G-protein-coupled receptors that primarily couple to Gs and elevate intracellular cAMP. Receptor selectivity defines the clinical effect. MC1R agonism on melanocytes stimulates eumelanin production through cAMP-dependent activation of microphthalmia-associated transcription factor (MITF) and downstream tyrosinase, TRP-1, and TRP-2 expression — producing the pigmentation effect that drives afamelanotide's EPP indication and the cosmetic interest in melanotan-I and melanotan-II. MC4R agonism in the hypothalamus (paraventricular nucleus, lateral hypothalamic area) drives appetite suppression and energy expenditure increase — the basis of setmelanotide's monogenic-obesity indication. MC3R agonism is less clearly characterized but contributes to feeding regulation and inflammation. MC4R and MC3R agonism in central sexual-arousal circuits underlies bremelanotide's HSDD indication.

The synthetic analogs differ in receptor selectivity and pharmacokinetics. Afamelanotide ([Nle4, D-Phe7]-α-MSH) is MC1R-selective with a long acting depot formulation (16 mg subcutaneous implant lasting ~2 months). Melanotan-I and afamelanotide share the same molecule; afamelanotide is the registered drug, melanotan-I is the research-channel name. Melanotan-II is a cyclic [Nle4, Asp5, D-Phe7, Lys10] analog with broader MC1R/MC3R/MC4R activity — explaining the dual pigmentation and sexual-arousal effects in early human studies. Setmelanotide is a cyclic MC4R-selective agonist, daily subcutaneous injection. Bremelanotide is a cyclic MC3R/MC4R agonist optimized for sexual-arousal effects without significant pigmentation. KPV is the C-terminal tripeptide of α-MSH (Lys-Pro-Val) with melanocortin-receptor-independent anti-inflammatory activity in colitis models. Nonapeptide-1 (Pal-Lys-Asp-α-MSH-9) is an MC1R antagonist used cosmetically for skin brightening — opposite direction from the tanning-targeted MC1R agonists.

The shared safety profile of injectable melanocortin analogs includes facial flushing, transient nausea, headaches, and pigmentation effects ranging from sun-tan-like darkening (intended for afamelanotide and the research-channel agents) to dramatic mole darkening that has prompted melanoma surveillance recommendations in melanotan-II users. Bremelanotide's most-cited safety effects are nausea (~40% of doses), facial flushing, headache, and transient blood pressure elevation. Setmelanotide is associated with skin hyperpigmentation, injection-site reactions, and spontaneous penile erections in male patients.

History & discovery

α-MSH was characterized in the 1950s and 1960s as a 13-residue peptide cleaved from the POMC precursor in the intermediate lobe of the pituitary, with effects on melanophore dispersion in fish and amphibians and on pigmentation in mammals. The five melanocortin receptors were cloned in the early 1990s — MC1R first, then MC2R-MC5R — establishing the receptor family that defines modern melanocortin pharmacology. POMC processing produces α-MSH, β-MSH, γ-MSH, ACTH, β-endorphin, and other peptide products through tissue-specific cleavage by prohormone convertases.

The synthetic analog era began in the 1980s with Mac Hadley and Victor Hruby's group at the University of Arizona, who developed melanotan-I (NDP-α-MSH) and melanotan-II as α-MSH analogs with enhanced potency and DPP-resistance for pigmentation studies. Melanotan-I (afamelanotide) used the [Nle4, D-Phe7] modification to resist degradation. Melanotan-II had additional cyclic structure for further potency. Both were developed as candidate sunless-tanning agents — α-MSH analogs that would activate MC1R in melanocytes to stimulate melanin production with photoprotective effect. The early translational interest in melanotan-I evolved through controlled-release formulations (Bhardwaj 2000, Pharmaceutical Research) into clinical development for erythropoietic protoporphyria — a rare genetic disorder characterized by extreme photosensitivity from accumulated photoactive porphyrins. Langendonk et al. (NEJM 2015) reported the pivotal Phase 3 trial showing that afamelanotide reduced sunlight-related pain and exposure restrictions in EPP patients, leading to FDA approval as Scenesse in 2019 and EMA approval earlier. Melanotan-II was never developed for any approved indication; its cyclic analog reached an unrelated approval pathway as bremelanotide for female sexual desire.

The MC4R obesity angle developed in parallel through human genetics. Krude et al. (Nat Genet 1998) reported that POMC mutations cause severe early-onset obesity, adrenal insufficiency, and red hair pigmentation in humans — establishing the MC4R hypothalamic feeding circuit (which is normally activated by POMC-derived α-MSH) as a major regulator of human body weight. MC4R mutations themselves were found to be the most common monogenic cause of severe obesity. This created a clear drug-target rationale: MC4R agonism in patients with POMC, MC4R, or related deficiency should restore the missing hypothalamic appetite-suppressing signal. Setmelanotide (Imcivree, Rhythm Pharmaceuticals) was developed as a selective MC4R agonist for this indication. Clement et al. (Lancet Diabetes & Endocrinology 2020) reported the Phase 3 trials in LEPR and POMC deficiency, leading to FDA approval in 2020 and subsequent expansions to PCSK1 deficiency and Bardet-Biedl syndrome. Setmelanotide does not work for typical (non-monogenic) obesity — the MC4R signaling pathway is intact in those patients, and the GLP-1 class is the appropriate therapy.

The sexual-arousal angle began with the unexpected observation that melanotan-II caused spontaneous erections in early human-volunteer studies — leading to the development of bremelanotide (PT-141) as a non-melanocyte-targeted MC3R/MC4R agonist for sexual dysfunction. Kingsberg et al. (Obstetrics & Gynecology 2019) reported the two RECONNECT Phase 3 trials in premenopausal women with hypoactive sexual desire disorder (HSDD), leading to FDA approval as Vyleesi in 2019. Bremelanotide is administered as a subcutaneous injection 45 minutes before anticipated sexual activity, with effects through central melanocortin receptors rather than peripheral pigmentation pathways. The cosmetic and research-channel use of melanotan-I and melanotan-II for sunless tanning continues despite no approval, with documented safety concerns including dramatic mole darkening, melanoma case reports, and unregulated formulation issues.

State of evidence

Evidence in this class is concentrated in three approved indications. For erythropoietic protoporphyria, afamelanotide has Phase 3 RCT support (Langendonk 2015 NEJM) plus extensive post-approval real-world data — the strongest evidence base in the family. For monogenic obesity (POMC, PCSK1, LEPR, BBS deficiency), setmelanotide has Phase 3 single-arm trial support (Clement 2020 Lancet Diabetes & Endocrinology) for the rare-disease indications. For HSDD in premenopausal women, bremelanotide has two Phase 3 RCTs (Kingsberg 2019 Obstetrics & Gynecology) as the basis for FDA approval.

Outside these approved indications, the evidence thins quickly. Melanotan-I is used outside its EPP-approved formulation in research-channel cosmetic-tanning settings; the pharmacology is real but the unregulated dosing and quality-control concerns make this a use case the medical literature uniformly cautions against. Melanotan-II has no clinical approval and substantial documented safety signals, including melanoma case reports in dermatology literature. KPV has preclinical anti-inflammatory data in colitis models with limited clinical translation. Nonapeptide-1 has cosmetic-grade data in skin-brightening formulations.

For patients, the practical takeaway is that the melanocortin class has three FDA-approved drugs each addressing a specific indication that the others do not — afamelanotide for EPP, setmelanotide for monogenic obesity, bremelanotide for HSDD — and significant research-channel and cosmetic activity outside those indications that has not produced validated clinical applications. Setmelanotide should not be confused with the GLP-1 class for general obesity; its mechanism of action is restricted to the small population with monogenic MC4R-pathway defects.

How members compare

Within the melanocortin family, the principal axis is receptor selectivity — pigmentation (MC1R) vs energy homeostasis (MC4R) vs sexual arousal (MC3R/MC4R). Afamelanotide is the MC1R-selective pigmentation agent. Setmelanotide is the MC4R-selective monogenic-obesity agent. Bremelanotide is the MC3R/MC4R sexual-arousal agent. Melanotan-II hits multiple receptors and underlies both the cosmetic-tanning use and the historical observation that led to bremelanotide's development. KPV and nonapeptide-1 sit at the periphery — KPV with melanocortin-receptor-independent anti-inflammatory effects, nonapeptide-1 as an MC1R antagonist for cosmetic skin brightening.

Outside the melanocortin family, the closest comparisons are GLP-1 receptor agonists for general obesity (the appropriate alternative to setmelanotide for non-monogenic obesity), PDE5 inhibitors and testosterone therapy for sexual-dysfunction indications other than HSDD (where bremelanotide is positioned), and topical melanin-targeting agents for cosmetic skin tone. For erythropoietic protoporphyria, afamelanotide has no close pharmacological alternative and represents the principal disease-modifying option.

Frequently asked questions

References

• Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humansOriginal Research

  Krude H, Biebermann H, Luck W, Horn R, Brabant G, and Gruters A, Nature Genetics 1998. The discovery paper showing that POMC mutations in humans cause severe early-onset obesity, adrenal insufficiency, and red hair pigmentation — establishing the human relevance of the MC4R hypothalamic feeding pathway and creating the rationale for setmelanotide's later development.

• Afamelanotide for Erythropoietic ProtoporphyriaClinical Trial

  Langendonk JG and colleagues, New England Journal of Medicine 2015. The pivotal Phase 3 trial showing that afamelanotide subcutaneous implants reduced sunlight-related pain and exposure restrictions in adults with erythropoietic protoporphyria. The basis for FDA (2019) and EMA (2014) approval as Scenesse — the only approved disease-modifying therapy for EPP.

• Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trialsClinical Trial

  Clement K and colleagues, Lancet Diabetes & Endocrinology 2020. The Phase 3 trials supporting setmelanotide's FDA approval for monogenic obesity in patients with LEPR or POMC deficiency. Established that selective MC4R agonism can restore appetite suppression in patients with upstream POMC-pathway defects — a meaningfully different pharmacology from the GLP-1 receptor agonist class for general obesity.

• Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 TrialsClinical Trial

  Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, and Simon JA, Obstetrics & Gynecology 2019. The two RECONNECT Phase 3 trials of bremelanotide in premenopausal women with hypoactive sexual desire disorder. Established the central MC3R/MC4R agonism mechanism for sexual desire and led to FDA approval of bremelanotide as Vyleesi in 2019.

• 60 YEARS OF POMC: Regulation of feeding and energy homeostasis by α-MSHReview

  Anderson EJ, Cakir I, Carrington SJ, Cone RD, Ghamari-Langroudi M, Gillyard T, Gimenez LE, and Litt MJ, Journal of Molecular Endocrinology 2016. The 60th-anniversary review of POMC and α-MSH biology, covering pigmentation, energy homeostasis, and the broader endocrinology of the melanocortin system. Standard single-source reference for the α-MSH literature.

• Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, Melanotan-IOriginal Research

Related goals